Skip to main content
ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.850
-0.440 (-13.37%)
At close: Mar 3, 2025, 4:00 PM
2.890
+0.040 (1.40%)
After-hours: Mar 3, 2025, 6:57 PM EST

ImmunityBio Revenue

In the year 2024, ImmunityBio had annual revenue of $14.75M with 2,270.58% growth. ImmunityBio had revenue of $7.55M in the quarter ending December 31, 2024, with 5,333.09% growth.

Revenue (ttm)
$14.75M
Revenue Growth
+2,270.58%
P/S Ratio
134.78
Revenue / Employee
$23,479
Employees
628
Market Cap
2.08B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202414.75M14.12M2,270.58%
Dec 31, 2023622.00K382.00K159.17%
Dec 31, 2022240.00K-694.00K-74.30%
Dec 31, 2021934.00K329.00K54.38%
Dec 31, 2020605.00K-1.60M-72.52%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 400.28B
Johnson & Johnson 88.82B
Merck & Co. 64.17B
AbbVie 56.33B
AstraZeneca 54.07B
Novartis AG 51.72B
Eli Lilly and Company 45.04B
Thermo Fisher Scientific 42.88B
Revenue Rankings

IBRX News

More News